Company History

Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.

Tokyo office was opened in Chiyoda-ku, Tokyo.

Business name was changed to HEALIOS K.K.
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.

Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.

Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.

Sighregen Co.,Ltd., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., (Current: Sumitomo Pharma Co., Ltd.) was established.

Main office was moved to Minato-ku, Tokyo.

Listed on the Tokyo Stock Exchange market Mothers (code: 4593).

A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.

Ophthalmic viscoelastic preparation business containing BBG250 was transferred to D. Western Therapeutics Institute, Inc.

Establishment of Healios NA, Inc. in USA

Adoption of International Financial Reporting Standards (IFRS)

Main office was moved to Chiyoda-ku, Tokyo.

Establish ment of fund subsidiaries in the field of regenerative medicine. including Saisei Ventures LLC in the U.S.

Moved to the Tokyo Stock Exchange Growth Market due to a revision of the market classification.

Establishment of subsidiary ProcellCure, Inc.

Acquisition of substantially all of the assets of Athersys, Inc

Basic Business Alliance Agreement and Bond Purchase Agreement with Alfresa Corporation

Establishment of Subsidiary Akatsuki Therapeutics, Inc.